Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharma intelligence for marketing agencies

Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.

Supporting market access strategy

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.

We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.

How it helps

You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.

Our accurate, reliable intelligence will help you:

Access in-depth knowledge from drug discovery to market access
Acquire a comprehensive understanding of the global pharma market
Get in-depth coverage of the entire pharmaceutical value-chain

Our unique strengths

Understand your clients’ world

Gain comprehensive knowledge of the global pharma market with our complete coverage.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking updates impacting the pharmaceutical industry.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

Scrip

Interview: Why Europe's Biotech Prime Time Is Now

By Sten Stovall 23 Oct 2019

VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.

Topic Business strategies Drug review

View article
Scrip

J&J's Spravato Set For EU Launches Soon

By Kevin Grogan 23 Oct 2019

Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the ﬁrst new mechanism of action in 30 years to treat major depressive disorder.

Topic Drug approval Drug development landscape

View article
Datamonitor Healthcare

Insight into NASH Pricing Strategies

By Hannah Cohen 21 Oct 2019

Explore the key hurdles to anticipating the initial and potential value of the NASH therapy market.

Topic Drug approval Business strategies

View white paper
Scrip

Survival Data Boost Lilly & Novartis's CDK4/6 Assault On Pfizer's Ibrance In Metastatic Breast Cancer

By Alex Shimmings 18 Oct 2019

Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.

Topic Cancer Drug development landscape Research

View article
Scrip

Ready, Set, Lowest: Who Won China's Latest Drug Bidding War?

By Brian Yang 18 Oct 2019

Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.

Topic Deal trends Strategy

View article
Scrip

Woodford Debacle Is A Test Of UK Biotech's Resilience

By Andrew McConaghie 18 Oct 2019

Investor's Downfall is Unwelcome Distraction: As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.

Topic BioPharmaceutical Company analysis

View article
Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 18 Oct 2019

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic Cell and gene therapy Drug development landscape

View article
Scrip

Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research

By Andrew McConaghie 18 Oct 2019

Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting.

Topic Research BioPharmaceutical

View article
Scrip

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

By Mandy Jackson 18 Oct 2019

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.

Topic Cell and gene therapy

View article
Pink Sheet

Pink Sheet Sample Article Pack: The Hottest Topics in Pharma Regulatory Compliance

16 Oct 2019

When you look at newly approved drugs, the latest product reviews and the decisions made during the process, you can gain critical insights to inform your own strategic decisions. That’s what Pink Sheet delivers, and now you can try it for free.

Topic Drug approval Drug development landscape

View article
Pink Sheet

Pink Sheet Performance Trackers: Navigate a complex world with the regulatory performance trackers from Pink Sheet

16 Oct 2019

Keep track of compliance, legislation, policy regulations, and industry developments with the expertise of our worldwide network of expert analysts and journalists on the ground in key global regions.

Topic Drug development landscape Drug review FDA

View article
Scrip

Opioids Crisis Commercial Implications for an Embattled Industry

14 Oct 2019

Find out how the consequences of the opioids crisis is affecting the pharma industry, from shaping the way deals are made, to transforming the development of new categories of drugs. Scrip brings you the implications behind the headlines in an essential free article pack.

Topic Drug development landscape FDA

View article
Pink Sheet

The Opioids Crisis Regulatory Response to an Epidemic

14 Oct 2019

With the opioid crisis in full swing in the US, government and regulatory agencies are announcing changes to guidance and legislation related to both new and existing drugs. Keep abreast of these critical changes with essential coverage from Pink Sheet.

Topic Drug approval FDA

View article
Datamonitor Healthcare

Providing Coverage of the Commercial Topics in Q3

10 Oct 2019

The Commercial Solutions Strategy Suite from Informa Pharma Intelligence unites the power of vital tools to bring you actionable data, penetrating analysis, and a crucial industry view covering a variety of critical market aspects, allowing you to accurately Forecast, Analyze and Benchmark, and Understand the mark landscape.

Topic Drug approval Drug development landscape

View article
Scrip, Pink Sheet, Generics Bulletin

Mega Mergers

30 Sep 2019

When it comes to M&A, Informa Pharma Insights has got it covered. Our readers benefit from exclusive executive interviews with industry leaders and expert analysts on business, pipeline and M&A strategy, broad and detailed coverage on implications of deal-making from antitrust to quality compliance, commercial and R&D infrastructure, regional repercussions and the impact on existing partners. 2019 has already been notable for major deals, from the closing of the $62bn Takeda/Shire acquisition to the agreed purchases of Celgene for $74bn by Bristol-Myers Squibb and of Allergan for $63bn by AbbVie, to Pfizer’s plan to merge its Upjohn generics business with Mylan.

Topic Business strategies

View article